SMO Sarah Cannon Research Inst.

Nashville, Tennessee 37203

We've found

1 trials

at this facility

A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Nashville, TN

Use our guide to learn which trials are right for you!